Onychomycosis Market Research Report - Forecast till 2027

Onychomycosis Market: Information by Type (Distal Subungual Onychomycosis (DSO), White Superficial Onychomycosis (WSO), Proximal Subungual Onychomycosis (PSO), Candida Onychomycosis and others), Treatment Type (Drug Treatment, Topical Therapy and others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027

ID: MRFR/Pharma/0832-CR | September 2019 | Region: Global | 122 pages

Onychomycosis Market Overview:
The Onychomycosis Market is expected to register a CAGR of 6.28% to reach 7,912.5 million by 2025. Onychomycosis refers to the fungal infection of the nail. The global onychomycosis market is expected to exhibit lucrative growth during the forecast period. Some of the major factors characterizing the market growth are the rising worldwide prevalence of onychomycosis, rising per capita healthcare expenditure, surging diabetic patient population, and increasing prevalence of peripheral artery disease (PAD). On the contrary, the side-effects associated with onychomycosis treatment drugs as well as lack of awareness about onychomycosis are anticipated to limit the market growth over the forecast period.


Market Dynamics


Onychomycosis also called tinea unguium, is a fungal infection of the toenails or fingernails that may involve any component of the nail unit, including the matrix, bed, or plate. An article published in the Journal of Tropical Medicine stated that, presently, the prevalence of onychomycosis mainly caused by non dermatophyte molds is increasing around the globe. The aging population, increased consumption of immunosuppressive-drugs-market-8228'>immunosuppressive drugs, rising prevalence of diseases such as human immunodeficiency virus (HIV) and diabetes that suppress the immune- status of patients, increased exposure to spas and public swimming pools, wearing tight-fitting shoes and clogs, and wearing sweaty footwears have been the factors for the rise in the incidence of mycoses. Onychomycosis represents 20% to 40% of all onycho-pathies around the globe. An article published on the ScienceDirect stated that, at present, worldwide onychomycosis prevalence ranges from 2% to 50%, and it represents approximately 30% of superficial mycotic infections and 50% of all nail disorders. Additionally, onychomycosis mainly affects adults between 30 and 60 years of age. Thus, this increasing prevalence of onychomycosis across the world is fueling the demand for treatment drugs and therapies around the globe, thereby supporting the market growth.


Global Onychomycosis Market Share, by Distribution Channel, 2018 (%)  Onychomycosis Market


Source: MRFR Analysis


Segmentation


The global onychomycosis market, by type, has been segmented into distal subungual onychomycosis (DSO), white superficial onychomycosis (WSO), proximal subungual onychomycosis (PSO), candida onychomycosis, and others. Based on treatment type, the global onychomycosis market has been segmented into drug treatment, topical therapy, and others. The global onychomycosis market, by distribution channel, has been segmented into hospital pharmacies, retail pharmacies, and others. The retail pharmacies segment held a share of 35.8% in 2018.


Asia-Pacific Onychomycosis Market Share, 2018 (%)  Onychomycosis Market


Source: MRFR Analysis


Regional Analysis


The global onychomycosis market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.


The Americas is expected to hold the largest share of the global onychomycosis market. This owes to the presence of key market participants, sophisticated healthcare infrastructure, increasing prevalence of onychomycosis and peripheral artery disease, rising per capita healthcare expenditure, and a surge in the diabetic patient population.


Europe is also expected to hold a substantial market share in the coming years. This is attributed to the rising geriatric population and increasing burden of diabetes, flourishing pharmaceutical industry, and growing occurrence rates of onychomycosis in the UK, Germany, France, and Spain.


Asia-Pacific is estimated to be the fastest-growing region in the global market due to the presence of huge older population, rapidly developing medical technology, growing disposable income, availability of drugs, and high unmet clinical needs. India held a share of 12.57% in onychomycosis market in 2018.


The onychomycosis market in the Middle East and Africa is expected to witness a modest market growth rate from 2019 to 2025. The Middle East would lead the market growth, attributing to facts such as increasing partnerships or agreements to commercialize onychomycosis products, developing healthcare infrastructure, booming medical tourism, budding healthcare industry, and growing awareness about onychomycosis and its treatment drugs and therapies.


Key Players



  • Novartis AG (Switzerland)

  • Pfizer, Inc. (the US)

  • Galderma Laboratories (Switzerland)

  • Bausch Health Sciences (Canada)

  • Moberg Pharma AB (Sweden)

  • Dr. Reddy’s Laboratories Ltd (India)

  • Medimetriks Pharmaceuticals, Inc. (US)

  • Merz Pharma (Germany)

  • Kaken Pharmaceutical Co., Ltd (Japan)

  • Johnson & Johnson Services, Inc. (US)

  • GlaxoSmithKline plc (UK)

  • Taro Pharmaceuticals Industries Ltd (Israel)


Some of the key strategies followed by players operating in the global onychomycosis market were innovation, product development, and acquisition & mergers.



  • In June 2019, Janssen Research & Development, LLC, part of the Janssen Pharmaceutical Companies of J&J Services announced a collaboration with the University of California, Berkeley and the University of California, San Francisco, to expand data science research in healthcare



  • In January 2019, Galderma Laboratories announced the opening of a new office in Malaysia, which would help it to accelerate the growth in the region



  • In November 2018, Moberg Pharma signed an exclusive agreement with Mundipharma to commercialize Emtrix in the Middle East and African region


Market Segmentation


Global Onychomycosis Market, by Type



  • Distal Subungual Onychomycosis (DSO)

  • White Superficial Onychomycosis (WSO)

  • Proximal Subungual Onychomycosis (PSO)

  • Candida Onychomycosis

  • Others


Global Onychomycosis Market, by Treatment Type



  • Drug Treatment

  • Topical Therapy

  • Others


Global Onychomycosis Market, by Distribution Channel



  • Hospital Pharmacies

  • Retail Pharmacies

  • Others


Global Onychomycosis Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America





  • Europe

    • Western Europe

      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa




Available Additional Customizations



  • Company Profiles of Other Key Players

    • Bayer AG

    • Glenmark

    • Enzon Pharmaceuticals, Inc.

    • Astellas Pharma, Inc.



  • Onychomycosis Market, Industry Trends

  • Investment Opportunities


Intended Audience



  • Pharmaceutical companies

  • Contract research manufacturing organizations

  • Research & development organizations

  • Academic institutes



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2025: USD 7,912.5 Million
  • 2027: Significant Value
  •   CAGR   6.28% (2019-2025)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type, Treatment Type and Distribution Channel
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Novartis AG (Switzerland), Pfizer, Inc. (the US), Galderma Laboratories (Switzerland), Bausch Health Sciences (Canada), Moberg Pharma AB (Sweden), Dr. Reddy’s Laboratories Ltd (India), Medimetriks Pharmaceuticals, Inc. (US), Merz Pharma (Germany), Kaken Pharmaceutical Co., Ltd (Japan), Johnson & Johnson Services, Inc. (US), GlaxoSmithKline plc (UK), and Taro Pharmaceuticals Industries Ltd (Israel)
      Key Market Opportunities   side-effects associated with onychomycosis treatment drugs
      Key Market Drivers

  • rising worldwide prevalence of onychomycosis
  • rising per capita healthcare expenditure
  • surging diabetic patient population
  • increasing prevalence of peripheral artery disease (PAD)


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    Onychomycosis Market CAGR would be 6.28% during the forecast period.

    Hike in healthcare expenditure, increasing diabetic patient population, and surge in prevalence in peripheral artery diseases (PAD) can drive Onychomycosis Market growth.

    Side-effects of the drugs and lack of awareness can prevent Onychomycosis Market growth.

    Retail pharmacies ruled Onychomycosis Market in 2018.

    The Americas would dominate Onychomycosis Market.

    1 Executive Summary

    1.1 Market Attractiveness Analysis 16

    2 Market Introduction

    2.1 Definition 19

    2.2 Scope Of The Study 19

    2.3 Assumptions 19

    2.4 Market Structure 20

    3 Research Methodology

    3.1 Research Process 21

    3.2 Data Mining 21

    3.3 Secondary Research 22

    3.4 Primary Research 23

    3.5 Forecasting Techniques 25

    3.6 Research Methodology For Market Size Estimation 27

    3.6.1 Bottom-Up Approach 27

    3.6.2 Top-Down Approach 28

    3.6.3 Data Triangulation 29

    3.6.4 Validation 29

    4 Market Dynamics

    4.1 Overview 30

    4.2 Drivers 31

    4.2.1 Worldwide Rising Prevalence Of Onychomycosis 31

    4.2.2 Rising Per Capita Healthcare Expenditure 31

    4.2.3 Surging Diabetic Patient Population 31

    4.2.4 Increasing Prevalence Of Peripheral Artery Disease (PAD) 31

    4.3 Restraints 32

    4.3.1 Lack Of Awareness About Onychomycosis 32

    4.3.2 Side-Effects Associated With Onychomycosis Treatment Drugs 32

    4.4 Opportunity 33

    4.4.1 Increase In The Number Of Pipeline Products 33

    5 Market Factor Analysis

    5.1 Porter’s Five Forces Model 34

    5.1.1 Bargaining Power Of Suppliers 34

    5.1.2 Bargaining Power Of Buyers 34

    5.1.3 Threat Of New Entrants 35

    5.1.4 Threat Of Substitutes 35

    5.1.5 Intensity Of Rivalry 35

    5.2 Value Chain Analysis 36

    5.2.1 R&D 36

    5.2.2 Manufacturing 36

    5.2.3 Distribution 36

    5.2.4 Marketing & Sales 36

    5.2.5 Post-Sales Monitoring 37

    6 Onychomycosis Market, By Type

    6.1 Overview 38

    6.2 Distal Subungual Onychomycosis 40

    6.3 White Superficial Onychomycosis 41

    6.4 Candida Onychomycosis 42

    6.5 Proximal Subungual Onychomycosis 43

    6.6 Others 43

    7 Onychomycosis Market, By Treatment Type

    7.1 Overview 44

    7.2 Drug Treatment 45

    7.3 Topical Therapy 46

    7.4 Others 46

    8 Onychomycosis Market, By Distribution Channel

    8.1 Overview 47

    8.2 Hospital Pharmacies 48

    8.3 Retail Pharmacies 49

    8.4 Others 49

    9 Global Onychomycosis Market, By Region

    9.1 Overview 50

    9.2 Americas 52

    Onychomycosis Market, By Type

    Onychomycosis Market, By Treatment Type

    Onychomycosis Market, By Distribution Channel

    9.2.1 North America 55

    Onychomycosis Market, By Type

    Onychomycosis Market, By Treatment Type

    Onychomycosis Market, By Distribution Channel

    9.2.1.1 US 57

    Onychomycosis Market, By Type

    Onychomycosis Market, By Treatment Type

    Onychomycosis Market, By Distribution Channel

    9.2.1.2 Canada 59

    Onychomycosis Market, By Type

    Onychomycosis Market, By Treatment Type

    Onychomycosis Market, By Distribution Channel

    9.2.2 Latin America 60

    Onychomycosis Market, By Type

    Onychomycosis Market, By Treatment Type

    Onychomycosis Market, By Distribution Channel

    9.3 Asia-Pacific 62

    Onychomycosis Market, By Type

    Onychomycosis Market, By Treatment Type

    Onychomycosis Market, By Distribution Channel

    9.3.1 Japan 65

    Onychomycosis Market, By Type

    Onychomycosis Market, By Treatment Type

    Onychomycosis Market, By Distribution Channel

    9.3.2 Australia 66

    Onychomycosis Market, By Type

    Onychomycosis Market, By Treatment Type

    Onychomycosis Market, By Distribution Channel

    9.3.3 China 68

    Onychomycosis Market, By Type

    Onychomycosis Market, By Treatment Type

    Onychomycosis Market, By Distribution Channel

    9.3.4 India 69

    Onychomycosis Market, By Type

    Onychomycosis Market, By Treatment Type

    Onychomycosis Market, By Distribution Channel

    9.3.5 South Korea 71

    Onychomycosis Market, By Type

    Onychomycosis Market, By Treatment Type

    Onychomycosis Market, By Distribution Channel

    9.3.6 Rest Of Asia-Pacific 72

    Onychomycosis Market, By Type

    Onychomycosis Market, By Treatment Type

    Onychomycosis Market, By Distribution Channel

    9.4 Europe 74

    Onychomycosis Market, By Type

    Onychomycosis Market, By Treatment Type

    Onychomycosis Market, By Distribution Channel

    9.4.1 Western Europe 77

    Onychomycosis Market, By Type

    Onychomycosis Market, By Treatment Type

    Onychomycosis Market, By Distribution Channel

    9.4.1.1 Germany 79

    Onychomycosis Market, By Type

    Onychomycosis Market, By Treatment Type

    Onychomycosis Market, By Distribution Channel

    9.4.1.2 France 81

    Onychomycosis Market, By Type

    Onychomycosis Market, By Treatment Type

    Onychomycosis Market, By Distribution Channel

    9.4.1.3 UK 82

    Onychomycosis Market, By Type

    Onychomycosis Market, By Treatment Type

    Onychomycosis Market, By Distribution Channel

    9.4.1.4 Italy 84

    Onychomycosis Market, By Type

    Onychomycosis Market, By Treatment Type

    Onychomycosis Market, By Distribution Channel

    9.4.1.5 Spain 85

    Onychomycosis Market, By Type

    Onychomycosis Market, By Treatment Type

    Onychomycosis Market, By Distribution Channel

    9.4.1.6 Rest Of Western Europe 87

    Onychomycosis Market, By Type

    Onychomycosis Market, By Treatment Type

    Onychomycosis Market, By Distribution Channel

    9.4.2 Eastern Europe 88

    Onychomycosis Market, By Type

    Onychomycosis Market, By Treatment Type

    Onychomycosis Market, By Distribution Channel

    9.5 Middle East & Africa 90

    Onychomycosis Market, By Type

    Onychomycosis Market, By Treatment Type

    Onychomycosis Market, By Distribution Channel

    9.5.1 Middle East 92

    Onychomycosis Market, By Type

    Onychomycosis Market, By Treatment Type

    Onychomycosis Market, By Distribution Channel

    9.5.2 Africa 94

    Onychomycosis Market, By Type

    Onychomycosis Market, By Treatment Type

    Onychomycosis Market, By Distribution Channel

    10 Competitive Landscape

    10.1 Overview 96

    11 Company Profile

    11.1 Bausch Health Companies, Inc. 98

    11.1.1 Company Overview 98

    11.1.2 Financial Overview 98

    11.1.3 Products/Services Offered 99

    11.1.4 Key Developments 99

    11.1.5 SWOT Analysis 99

    11.1.6 Key Strategies 99

    11.2 Dr. Reddy’s Laboratories Ltd 100

    11.2.1 Company Overview 100

    11.2.2 Financial Overview 100

    11.2.3 Products/Services Offered 101

    11.2.4 Key Developments 101

    11.2.5 SWOT Analysis 101

    11.2.6 Key Strategies 101

    11.3 Galderma Laboratories 102

    11.3.1 Company Overview 102

    11.3.2 Financial Overview 102

    11.3.3 Products/Services Offered 103

    11.3.4 Key Developments 103

    11.3.5 SWOT Analysis 103

    11.3.6 Key Strategies 103

    11.4 GlaxoSmithKline PLC 104

    11.4.1 Company Overview 104

    11.4.2 Financial Overview 104

    11.4.3 Products/Services Offered 105

    11.4.4 Key Developments 105

    11.4.5 SWOT Analysis 105

    11.4.6 Key Strategies 105

    11.5 Johnson & Johnson Services Inc. 106

    11.5.1 Company Overview 106

    11.5.2 Financial Overview 106

    11.5.3 Products/Services Offered 107

    11.5.4 Key Developments 107

    11.5.5 SWOT Analysis 107

    11.5.6 Key Strategies 107

    11.6 Kaken Pharmaceutical Co., Ltd 108

    11.6.1 Company Overview 108

    11.6.2 Financial Overview 108

    11.6.3 Products/Services Offered 108

    11.6.4 Key Developments 109

    11.6.5 SWOT Analysis 109

    11.6.6 Key Strategies 109

    11.7 Merz Pharma 110

    11.7.1 Company Overview 110

    11.7.2 Financial Overview 110

    11.7.3 Products/Services Offered 110

    11.7.4 Key Developments 110

    11.7.5 SWOT Analysis 110

    11.7.6 Key Strategies 111

    11.8 Moberg Pharma AB 112

    11.8.1 Company Overview 112

    11.8.2 Financial Overview 112

    11.8.3 Products/Services Offered 113

    11.8.4 Key Developments 113

    11.8.5 SWOT Analysis 113

    11.8.6 Key Strategies 113

    11.9 Medimetriks Pharmaceuticals, Inc. 114

    11.9.1 Company Overview 114

    11.9.2 Financial Overview 114

    11.9.3 Products/Services Offered 114

    11.9.4 Key Developments 114

    11.9.5 SWOT Analysis 114

    11.9.6 Key Strategy 115

    11.10 Novartis AG 116

    11.10.1 Company Overview 116

    11.10.2 Financial Overview 116

    11.10.3 Products/Services Offered 117

    11.10.4 Key Developments 117

    11.10.5 SWOT Analysis 117

    11.10.6 Key Strategies 117

    11.11 Pfizer, Inc. 118

    11.11.1 Company Overview 118

    11.11.2 Financial Overview 118

    11.11.3 Products/Services Offered 119

    11.11.4 Key Developments 119

    11.11.5 SWOT Analysis 119

    11.11.6 Key Strategies 119

    11.12 Taro Pharmaceuticals Industries Ltd 120

    11.12.1 Company Overview 120

    11.12.2 Financial Overview 120

    11.12.3 Products/Services Offered 121

    11.12.4 Key Developments 121

    11.12.5 SWOT Analysis 121

    11.12.6 Key Strategies 121

    12 Appendix

    12.1 References 122

    12.2 Related Reports 122


    13 List Of Tables

    TABLE 1 LIST OF ASSUMPTIONS 19

    TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 24

    TABLE 3 ONYCHOMYCOSIS TREATMENT DRUGS PIPELINE 33

    TABLE 4 GLOBAL ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 39

    TABLE 5 GLOBAL ONYCHOMYCOSIS MARKET FOR DISTAL SUBUNGUAL ONYCHOMYCOSIS, BY REGION 2020–2027 (USD MILLION) 40

    TABLE 6 GLOBAL ONYCHOMYCOSIS MARKET FOR WHITE SUPERFICIAL ONYCHOMYCOSIS, BY REGION 2020–2027 (USD MILLION) 41

    TABLE 7 GLOBAL ONYCHOMYCOSIS MARKET FOR CANDIDA ONYCHOMYCOSIS, BY REGION 2020–2027 (USD MILLION) 42

    TABLE 8 GLOBAL ONYCHOMYCOSIS MARKET FOR PROXIMAL SUBUNGUAL ONYCHOMYCOSIS, BY REGION 2020–2027 (USD MILLION) 43

    TABLE 9 GLOBAL ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 45

    TABLE 10 GLOBAL ONYCHOMYCOSIS MARKET FOR DRUG TREATMENT, BY REGION 2020–2027 (USD MILLION) 45

    TABLE 11 GLOBAL ONYCHOMYCOSIS MARKET FOR TOPICAL THERAPY, BY REGION 2020–2027 (USD MILLION) 46

    TABLE 12 GLOBAL ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027, (USD MILLION) 48

    TABLE 13 GLOBAL ONYCHOMYCOSIS MARKET FOR HOSPITAL PHARMACIES, BY REGION 2020–2027 (USD MILLION) 48

    TABLE 14 GLOBAL ONYCHOMYCOSIS MARKET FOR RETAIL PHARMACIES, BY REGION 2020–2027 (USD MILLION) 49

    TABLE 15 GLOBAL ONYCHOMYCOSIS MARKET, BY REGION, 2020–2027 (USD MILLION) 51

    TABLE 16 AMERICAS: ONYCHOMYCOSIS MARKET, BY REGION, 2020–2027 (USD MILLION) 53

    TABLE 17 AMERICAS: ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 53

    TABLE 18 AMERICAS: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 54

    TABLE 19 AMERICAS: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 54

    TABLE 20 NORTH AMERICA: ONYCHOMYCOSIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 55

    TABLE 21 NORTH AMERICA: ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 56

    TABLE 22 NORTH AMERICA: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 56

    TABLE 23 NORTH AMERICA: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 57

    TABLE 24 US: ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027, (USD MILLION) 57

    TABLE 25 US: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027, (USD MILLION) 58

    TABLE 26 US: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027, (USD MILLION) 58

    TABLE 27 CANADA: ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027, (USD MILLION) 59

    TABLE 28 CANADA: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027, (USD MILLION) 59

    TABLE 29 CANADA: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027, (USD MILLION) 60

    TABLE 30 LATIN AMERICA: ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 60

    TABLE 31 LATIN AMERICA: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 61

    TABLE 32 LATIN AMERICA: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 61

    TABLE 33 ASIA-PACIFIC: ONYCHOMYCOSIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 63

    TABLE 34 ASIA-PACIFIC: ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 63

    TABLE 35 ASIA-PACIFIC: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 64

    TABLE 36 ASIA-PACIFIC: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 64

    TABLE 37 JAPAN: ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 65

    TABLE 38 JAPAN: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 65

    TABLE 39 JAPAN: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 66

    TABLE 40 AUSTRALIA: ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 66

    TABLE 41 AUSTRALIA: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 67

    TABLE 42 AUSTRALIA: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 67

    TABLE 43 CHINA: ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 68

    TABLE 44 CHINA: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 68

    TABLE 45 CHINA: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 69

    TABLE 46 INDIA: ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 69

    TABLE 47 INDIA: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 70

    TABLE 48 INDIA: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 70

    TABLE 49 SOUTH KOREA: ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 71

    TABLE 50 SOUTH KOREA: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 71

    TABLE 51 SOUTH KOREA: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 72

    TABLE 52 REST OF ASIA-PACIFIC: ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 72

    TABLE 53 REST OF ASIA-PACIFIC: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 73

    TABLE 54 REST OF ASIA-PACIFIC: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 73

    TABLE 55 EUROPE: ONYCHOMYCOSIS MARKET, BY REGION, 2020–2027 (USD MILLION) 75

    TABLE 56 EUROPE: ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 75

    TABLE 57 EUROPE: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 76

    TABLE 58 EUROPE: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 76

    TABLE 59 WESTERN EUROPE: ONYCHOMYCOSIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 77

    TABLE 60 WESTERN EUROPE: ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 78

    TABLE 61 WESTERN EUROPE: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 78

    TABLE 62 WESTERN EUROPE: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 79

    TABLE 63 GERMANY: ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 79

    TABLE 64 GERMANY: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 80

    TABLE 65 GERMANY: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 80

    TABLE 66 FRANCE: ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 81

    TABLE 67 FRANCE: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 81

    TABLE 68 FRANCE: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 82

    TABLE 69 UK: ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 82

    TABLE 70 UK: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 83

    TABLE 71 UK: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 83

    TABLE 72 ITALY: ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 84

    TABLE 73 ITALY: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 84

    TABLE 74 ITALY: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 85

    TABLE 75 SPAIN: ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 85

    TABLE 76 SPAIN: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 86

    TABLE 77 SPAIN: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 86

    TABLE 78 REST OF WESTERN EUROPE: ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 87

    TABLE 79 REST OF WESTERN EUROPE: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 87

    TABLE 80 REST OF WESTERN EUROPE: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 88

    TABLE 81 EASTERN EUROPE: ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 88

    TABLE 82 EASTERN EUROPE: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 89

    TABLE 83 EASTERN EUROPE: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 89

    TABLE 84 MIDDLE EAST & AFRICA: ONYCHOMYCOSIS MARKET, BY REGION, 2020 AND 2027 90

    TABLE 85 MIDDLE EAST & AFRICA: ONYCHOMYCOSIS MARKET, BY REGION, 2020–2027 (USD MILLION) 90

    TABLE 86 MIDDLE EAST & AFRICA: ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 91

    TABLE 87 MIDDLE EAST & AFRICA: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 91

    TABLE 88 MIDDLE EAST & AFRICA: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 92

    TABLE 89 MIDDLE EAST: ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 92

    TABLE 90 MIDDLE EAST: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 93

    TABLE 91 MIDDLE EAST: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 93

    TABLE 92 AFRICA: ONYCHOMYCOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 94

    TABLE 93 AFRICA: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 94

    TABLE 94 AFRICA: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 95

    TABLE 95 GLOBAL ONYCHOMYCOSIS MARKET: COMPANY SHARE ANALYSIS, 2020 (%) 96


    14 List Of Figures

    FIGURE 1 MARKET SYNOPSIS 15

    FIGURE 2 MARKET ATTRACTIVENESS ANALYSIS: GLOBAL ONYCHOMYCOSIS MARKET 16

    FIGURE 3 GLOBAL ONYCHOMYCOSIS MARKET SHARE, BY TYPE, 2020 (%) 16

    FIGURE 4 GLOBAL ONYCHOMYCOSIS MARKET, BY TYPE, 2017–2027 (USD MILLION) 17

    FIGURE 5 GLOBAL ONYCHOMYCOSIS MARKET SHARE, BY TREATMENT TYPE, 2020 (%) 17

    FIGURE 6 GLOBAL ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2017–2027 (USD MILLION) 17

    FIGURE 7 GLOBAL ONYCHOMYCOSIS MARKET SHARE, BY DISTRIBUTION CHANNEL, 2020 (%) 18

    FIGURE 8 GLOBAL ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION) 18

    FIGURE 9 GLOBAL ONYCHOMYCOSIS MARKET: MARKET STRUCTURE 20

    FIGURE 10 PRIMARY RESPONDENT’S BREAKDOWN 24

    FIGURE 11 BOTTOM-UP AND TOP-DOWN APPROACH 27

    FIGURE 12 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL ONYCHOMYCOSIS MARKET 30

    FIGURE 13 PORTER’S FIVE FORCES ANALYSIS: GLOBAL ONYCHOMYCOSIS MARKET 34

    FIGURE 14 VALUE CHAIN ANALYSIS OF THE GLOBAL ONYCHOMYCOSISMARKET 36

    FIGURE 15 GLOBAL ONYCHOMYCOSIS MARKET SHARE, BY TYPE, 2020 (%) 38

    FIGURE 16 GLOBAL ONYCHOMYCOSIS MARKET, BY TYPE, 2020 AND 2027 (USD MILLION) 39

    FIGURE 17 GLOBAL ONYCHOMYCOSIS MARKET SHARE, BY TREATMENT TYPE, 2020 (%) 44

    FIGURE 18 GLOBAL ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2020 AND 2027 (USD MILLION) 44

    FIGURE 19 GLOBAL ONYCHOMYCOSIS MARKET SHARE, BY DISTRIBUTION CHANNEL, 2020 (%) 47

    FIGURE 20 GLOBAL ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2020 AND 2027 (USD MILLION) 47

    FIGURE 21 GLOBAL ONYCHOMYCOSIS MARKET SHARE, BY REGION, 2020 (%) 50

    FIGURE 22 GLOBAL ONYCHOMYCOSIS MARKET, BY REGION, 2020 AND 2027 (USD MILLION) 51

    FIGURE 23 AMERICAS: ONYCHOMYCOSIS MARKET, BY REGION, 2020 AND 2027 52

    FIGURE 24 NORTH AMERICA: ONYCHOMYCOSIS MARKET, BY COUNTRY, 2020 AND 2027 55

    FIGURE 25 ASIA-PACIFIC: ONYCHOMYCOSIS MARKET, BY COUNTRY, 2020 AND 2027 62

    FIGURE 26 EUROPE: ONYCHOMYCOSIS MARKET, BY REGION, 2020 AND 2027 74

    FIGURE 27 WESTERN EUROPE: ONYCHOMYCOSIS MARKET, BY COUNTRY, 2020 AND 2027 77